|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...1516171819202122232425...4041» |
- Clinical: Aerobic Exercise and Flu-like Symptoms Following Interferon Beta 1a Injections in Patients With Multiple Sclerosis? (clinicaltrials.gov) - Sep 10, 2014
P=N/A, N=20, Recruiting, Sponsor: University of Aarhus
- Trial completion, Enrollment change, Trial primary completion date: Electrical Impedance Myography as an Outcome Measure in Amyotrophic Lateral Sclerosis Clinical Trials (clinicaltrials.gov) - Sep 10, 2014
P=N/A, N=89, Completed, Sponsor: Beth Israel Deaconess Medical Center
Active, not recruiting --> Completed | N=120 --> 89 | Trial primary completion date: Mar 2009 --> Mar 2011
- ||| opicinumab (BIIB033) / Biogen, Avonex (recombinant IFN-β-1a) / Biogen
Enrollment closed, Trial primary completion date: SYNERGY: Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (clinicaltrials.gov) - Sep 9, 2014
P2, N=419, Active, not recruiting, Sponsor: Biogen Idec
Active, not recruiting --> Completed | N=120 --> 89 | Trial primary completion date: Mar 2009 --> Mar 2011 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Mar 2016
- ||| Avonex (recombinant IFN-β-1a) / Biogen
Trial completion, HEOR, Adherence: Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™. (clinicaltrials.gov) - Sep 9, 2014
P=N/A, N=270, Completed, Sponsor: Biogen Idec
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Mar 2016 Active, not recruiting --> Completed
- ||||| Plegridy (PEG-interferon ?-1a) / Biogen
New P4 trial: Frequency: Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy (clinicaltrials.gov) - Sep 9, 2014
P4, N=1200, Not yet recruiting, Sponsor: Biogen Idec
- ||||| teriflunomide / Generic mfg.
Enrollment closed, Immune cell: Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis (clinicaltrials.gov) - Sep 5, 2014
P3, N=68, Active, not recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| dimethyl fumarate / Generic mfg., aspirin / Generic mfg.
Enrollment open, P4 data: Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Sep 4, 2014
P4, N=240, Recruiting, Sponsor: Biogen Idec
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Enrollment closed: Extension Study of MT-1303 (clinicaltrials.gov) - Sep 4, 2014
P2, N=400, Active, not recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Enrollment closed, Trial primary completion date: Using Optical Coherence Tomography to Capture Retinal Microvascular Changes Associated With Multiple Sclerosis (clinicaltrials.gov) - Sep 4, 2014
P=N/A, N=80, Active, not recruiting, Sponsor: Oregon Health and Science University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jun 2015
- Trial completion, Trial primary completion date, Stroma: Assessment of the Subcutaneous Reinjection of Human Autologous Adipose-derived Stromal Vascular Fraction (Celution (clinicaltrials.gov) - Sep 4, 2014
P=N/A, N=12, Completed, Sponsor: Assistance Publique Hopitaux De Marseille
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jun 2015 Recruiting --> Completed | Trial primary completion date: Nov 2014 --> Nov 2013
- | Tysabri (natalizumab) / Biogen, Royalty
Trial termination, Trial primary completion date: STRATA: Natalizumab (Tysabri) Re-Initiation of Dosing (clinicaltrials.gov) - Aug 29, 2014
P3, N=716, Terminated, Sponsor: Biogen Idec
Recruiting --> Completed | Trial primary completion date: Nov 2014 --> Nov 2013 Active, not recruiting --> Terminated | Trial primary completion date: Jan 2014 --> Apr 2014
- | MIS416 / Amplia Therap
New P2b trial: Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Aug 29, 2014
P2b, N=90, Recruiting, Sponsor: Innate Immunotherapeutics
- | Vitaros (alprostadil + novel excipient) / Seelos Therap
New P2 trial: Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (clinicaltrials.gov) - Aug 29, 2014
P2, N=45, Not yet recruiting, Sponsor: NexMed, Inc.
- ||| Betaseron (IFN-?-1b) / Bayer
Trial completion, Adherence: SEPLUS: Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period (clinicaltrials.gov) - Aug 29, 2014
P=N/A, N=80, Completed, Sponsor: Bayer
Active, not recruiting --> Terminated | Trial primary completion date: Jan 2014 --> Apr 2014 Active, not recruiting --> Completed
- Enrollment open: Balance and Falls in Multiple Sclerosis (clinicaltrials.gov) - Aug 26, 2014
P=N/A, N=50, Recruiting, Sponsor: Örebro County Council
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- fingolimod / Generic mfg.
Clinical: Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya. (clinicaltrials.gov) - Aug 26, 2014
P=N/A, N=125, Recruiting, Sponsor: University of Southern California
- Trial primary completion date: CTSM: Effects of the Cross-Training in Patients With Multiple Sclerosis (clinicaltrials.gov) - Aug 25, 2014
P1/2, N=45, Recruiting, Sponsor: Università degli Studi di Sassari
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2014 --> Nov 2014
- selurampanel (BGG492) / Novartis
Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date: Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis (clinicaltrials.gov) - Aug 22, 2014
P2, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Mar 2014 --> Nov 2014 N=145 --> 0 | Initiation date: Nov 2012 --> Oct 2016 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2013 --> Mar 2018
- ||||| vatelizumab (GBR 500) / Glenmark
New P2 trial: Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Aug 22, 2014
P2, N=168, Not yet recruiting, Sponsor: Genzyme, a Sanofi Company
- | teriflunomide / Generic mfg.
Trial completion: A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers (clinicaltrials.gov) - Aug 21, 2014
P1, N=12, Completed, Sponsor: Sanofi
N=145 --> 0 | Initiation date: Nov 2012 --> Oct 2016 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2013 --> Mar 2018 Active, not recruiting --> Completed
- || Trial primary completion date: Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns (clinicaltrials.gov) - Aug 19, 2014
P4, N=240, Recruiting, Sponsor: Allergan
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Jun 2015
- |||| Tysabri (natalizumab) / Biogen, Royalty
Trial primary completion date: ASCEND: A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Aug 19, 2014
P3, N=890, Active, not recruiting, Sponsor: Biogen Idec
Trial primary completion date: Dec 2014 --> Jun 2015 Trial primary completion date: Dec 2014 --> Oct 2015
- |||||||||| dalfampridine / Generic mfg.
New P3 trial: ENHANCE: Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis (clinicaltrials.gov) - Aug 19, 2014
P3, N=590, Not yet recruiting, Sponsor: Biogen Idec
- Enrollment closed: Wahls Paleo Diet and Progressive Multiple Sclerosis (clinicaltrials.gov) - Aug 19, 2014
P=N/A, N=45, Active, not recruiting, Sponsor: University of Iowa
Trial primary completion date: Dec 2014 --> Oct 2015 Recruiting --> Active, not recruiting
- Tysabri (natalizumab) / Biogen, Royalty
Trial primary completion date: PK and PD Study of Natalizumab in Pediatric Subjects With RRMS (clinicaltrials.gov) - Aug 19, 2014
P1, N=12, Recruiting, Sponsor: Biogen Idec
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2015 --> Apr 2015
- l-methylfolate / Generic mfg.
Trial primary completion date: Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS) (clinicaltrials.gov) - Aug 19, 2014
P1, N=40, Active, not recruiting, Sponsor: University of Iowa
Trial primary completion date: Sep 2015 --> Apr 2015 Trial primary completion date: Jan 2014 --> Jan 2016
- dimethyl fumarate / Generic mfg.
Preclinical: Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS (clinicaltrials.gov) - Aug 19, 2014
P=N/A, N=20, Recruiting, Sponsor: Yale University
- ||| ZB-168 / Zura Bio
Enrollment open: A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS) (clinicaltrials.gov) - Aug 19, 2014
P1, N=60, Recruiting, Sponsor: Pfizer
Trial primary completion date: Jan 2014 --> Jan 2016 Not yet recruiting --> Recruiting
- Orencia (abatacept) / BMS
Enrollment change: ACCLAIM: A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (clinicaltrials.gov) - Aug 15, 2014
P2, N=65, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting N=123 --> 65
- ||||| dimethyl fumarate / Generic mfg.
New P4 trial: IIT9: Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation (clinicaltrials.gov) - Aug 15, 2014
P4, N=100, Recruiting, Sponsor: Rocky Mountain MS Research Group, LLC
- | Rebif (human IFN-β-1a) / EMD Serono
Trial completion, Trial primary completion date: ReNew: Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=49, Completed, Sponsor: Merck KGaA
N=123 --> 65 Active, not recruiting --> Completed | Trial primary completion date: May 2012 --> Apr 2013
- | Trial completion: Expiratory Muscle Training for Persons With Neurodegenerative Disease (clinicaltrials.gov) - Aug 15, 2014
P2/3, N=90, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed | Trial primary completion date: May 2012 --> Apr 2013 Active, not recruiting --> Completed
- ||| Tysabri (natalizumab) / Biogen, Royalty
Trial completion, Enrollment change, Trial primary completion date: Pregnancy Exposure Registry for Tysabri® (clinicaltrials.gov) - Aug 11, 2014
P=N/A, N=376, Completed, Sponsor: Biogen Idec
Active, not recruiting --> Completed Recruiting --> Completed | N=300 --> 376 | Trial primary completion date: Jun 2016 --> Jul 2012
- |||| Trial completion, Patient reported outcomes: Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) (clinicaltrials.gov) - Aug 8, 2014
P4, N=298, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=300 --> 376 | Trial primary completion date: Jun 2016 --> Jul 2012 Active, not recruiting --> Completed
- amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Enrollment open: A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303 (clinicaltrials.gov) - Aug 8, 2014
P1, N=0, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | arimoclomol (OR-01) / Orphazyme, KemPharm
Enrollment closed: Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Aug 7, 2014
P2/3, N=80, Active, not recruiting, Sponsor: University of Miami
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Clinical: Balance and Falls in Multiple Sclerosis (clinicaltrials.gov) - Aug 6, 2014
P=N/A, N=50, Not yet recruiting, Sponsor: Örebro County Council
- Enrollment open, HEOR: PDMSLac: Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis Patients (clinicaltrials.gov) - Aug 6, 2014
P=N/A, N=39, Recruiting, Sponsor: Florida State University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases (clinicaltrials.gov) - Aug 6, 2014
P=N/A, N=19, Completed, Sponsor: Wake Forest Baptist Health
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial primary completion date: Mechanical Stress Effects on the Cardiovascular Adaptations of Peripheral Arterial Calcifications Among Athletes (clinicaltrials.gov) - Aug 5, 2014
P=N/A, N=90, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
Recruiting --> Completed Trial primary completion date: Jul 2014 --> Mar 2015
- || Enrollment closed, Trial primary completion date: LARMES: Tear Analysis in the Diagnosis of Multiple Sclerosis (clinicaltrials.gov) - Aug 5, 2014
P=N/A, N=100, Active, not recruiting, Sponsor: Lille Catholic University
Trial primary completion date: Jul 2014 --> Mar 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Mar 2016
- | Cosentyx (secukinumab) / Novartis
Trial completion, Enrollment change, Trial primary completion date: Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis (clinicaltrials.gov) - Aug 4, 2014
P2, N=28, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Mar 2016 Recruiting --> Completed | N=380 --> 28 | Trial primary completion date: Oct 2015 --> Apr 2014
- |||| Rebif (human IFN-β-1a) / EMD Serono
Trial completion: Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Aug 4, 2014
P4, N=764, Completed, Sponsor: EMD Serono
Recruiting --> Completed | N=380 --> 28 | Trial primary completion date: Oct 2015 --> Apr 2014 No longer recruiting --> Completed
- Biomarker, Trial primary completion date: A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis (clinicaltrials.gov) - Aug 1, 2014
P=N/A, N=45, Recruiting, Sponsor: John F. Foley, MD
No longer recruiting --> Completed Trial primary completion date: May 2014 --> May 2015
- Myoconda (clarithromycin/clofazimine/rifabutin) / RedHill
Trial primary completion date: CEASE-MS: Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Aug 1, 2014
P2a, N=16, Recruiting, Sponsor: RedHill Biopharma Limited
Trial primary completion date: May 2014 --> May 2015 Trial primary completion date: Jun 2014 --> May 2015
- Tysabri (natalizumab) / Biogen, Royalty, Fumaderm (dimethyl fumarate) / Biogen
Enrollment closed: IIT6: Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design (clinicaltrials.gov) - Aug 1, 2014
P=N/A, N=30, Active, not recruiting, Sponsor: Rocky Mountain MS Research Group, LLC
Trial primary completion date: Jun 2014 --> May 2015 Recruiting --> Active, not recruiting
- ||||| Lemtrada (alemtuzumab) / Sanofi
Clinical: EMERALD: Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA (clinicaltrials.gov) - Aug 1, 2014
P4, N=56, Not yet recruiting, Sponsor: Genzyme, a Sanofi Company
- Rituxan (rituximab) / Roche
Enrollment closed, Trial primary completion date: Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease (clinicaltrials.gov) - Aug 1, 2014
P2, N=74, Active, not recruiting, Sponsor: Lee, Stephanie
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Mar 2015
- dextromethorphan hydrobromide/quinidine sulfate / Generic mfg.
Trial primary completion date: Clinical Trial Nuedexta in Subjects With ALS (clinicaltrials.gov) - Jul 30, 2014
P2, N=60, Recruiting, Sponsor: Center for Neurologic Study, La Jolla, California,
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Mar 2015 Trial primary completion date: Oct 2014 --> Apr 2015
- ||||| Plegridy (PEG-interferon β-1a) / Biogen
Enrollment closed: Long-Term Safety and Efficacy Study of Peginterferon Beta-1a (clinicaltrials.gov) - Jul 30, 2014
P3, N=1500, Active, not recruiting, Sponsor: Biogen Idec
Trial primary completion date: Oct 2014 --> Apr 2015 Enrolling by invitation --> Active, not recruiting